One man used Claude to find cure for rare muscle diseases, now Anthropic is buying his startup

On X, there is an account which goes by the username @Prof_Oak_ -- a reference to the famous Pokemon researcher Professor Samuel Oak from the TV show. On Tuesday night, however, Professor Oak made a surprising announcement. This Professor Oak was in fact leading a one-person biotech lab that had just been acquired by Anthropic.“Surprise 1: Anthropic acquired a one-person biotech. Surprise 2: that person is me,” Professor Oak wrote on X. The person identified themselves as Cody Tranbarger.Tranbarger revealed that roughly 18 months ago, he created Mithril Medicine to work on medical treatment. Unlike other medical labs, Mithril Medicine took a different approach to research. It had only Cody Tranbarger as a human worker – the rest was handled by Anthropic’s Claude models.Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All— Professor Oak (@Prof_Oak_) October 27, 2026In a LinkedIn post, Cody Tranbarger stated that Anthropic had acquired his biotech firm in July this year. As per his LinkedIn profile,Tranbarger is an Entrepreneur-in-Residence at the VC firm Atlas Venture. He has an MBA from Harvard Business School. Claude helped one man manage a biotechMithril operated virtually with Tranbarger as its only full-time employee, but it did have paid consultants. Claude helped manage experiments, data, contracts and logistics across outside laboratories. In a blog post on speeding up drug discovery, Anthropic mentioned that it had acquired Mithril Medicine. Anthropic called the biotech’s model “Pipeline-in-a-Person.”Cody Tranbarger said the approach began as an experiment to determine how far a single operator, Claude and part-time consultants could scale. This setup did bring in results. Mithril reported mouse proof of principle for its LAMA2 programme in under 18 months. Seven mice receiving one antibody format showed about twice the grip strength and peak triceps force of four control mice. “As a result, Mithril took a possible treatment for one form of muscular dystrophy from an idea to promising results in mice in less than 18 months,” Anthropic said. However, treatment was not randomised, testing occurred at different times and the colony moved between experiments. The technical report also awaits peer review.More resources for medical research at AnthropicCody Tranbarger insisted that by joining Anthropic he would have more resources to continue his work, alongside other programmes. He termed it as an “almost unprecedented luxury for a curious drug hunter.” The internet’s Professor Oak signed off his announcement post with the iconic catch phrase, “gotta catch ‘em all.”Meanwhile, Anthropic said that Tranbarger’s work on muscular dystrophy could soon lead to clinical trials. “If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028,” the post explained.Anthropic has been working towards speeding up drug discovery with AI. The company has made progress in some cases, such as Claude discovering a CRISPR-like gene editing system. Mithril Medicine’s acquisition forms part of Anthropic’s wider life-sciences work with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. These collaborations cover molecule design, lead optimisation, manufacturing records, regulatory filings, company creation and clinical-trial planning.- Ends